UCB sells Celltech for €27.5 million

By Kimberly N. Alleyne

Stroudsburg, Pa., Aug. 26 - UCB announced Friday it has sold its Celltech Manufacturing Services Ltd. subsidiary to Inyx Inc. for €27.5 million.

Celltech is an Ashton, United Kingdom, contract manufacturer. Inyx is a U.S. specialty pharmaceutical company that focuses on niche drug delivery technologies.

UCB is a global biopharmaceutical company with headquarters in Brussels, Belgium, specializing in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.